PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25284689-3	2014	By using quantitative real-time PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA), we show that either ectopic expression of orphan nuclear receptor Nur77 or pharmacological activation of Nur77 by 6-mercaptopurine (6-MP) substantially inhibits ET-1 expression in human umbilical vein endothelial cells (HUVECs), under both basal and thrombin-stimulated conditions.	Mercaptopurine	207-223	nuclear receptor subfamily 4 group A member 1	Homo sapiens	159-164	
31273046-0	2019	Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling.	Mercaptopurine	73-89	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-64	
31273046-3	2019	Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients.	Mercaptopurine	229-245	nuclear receptor subfamily 4 group A member 1	Homo sapiens	24-29	
31273046-3	2019	Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients.	Mercaptopurine	229-245	nuclear receptor subfamily 4 group A member 1	Homo sapiens	220-225	
31273046-3	2019	Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients.	Mercaptopurine	229-245	nuclear receptor subfamily 4 group A member 1	Homo sapiens	220-225	
31273046-3	2019	Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients.	Mercaptopurine	247-251	nuclear receptor subfamily 4 group A member 1	Homo sapiens	220-225	
31273046-3	2019	Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients.	Mercaptopurine	247-251	nuclear receptor subfamily 4 group A member 1	Homo sapiens	220-225	
30123220-7	2018	Treatment of human moDCs with 6-mercaptopurine, an activator of Nur77, leads to diminished DC activation resulting in an impaired capacity to induce IFNgamma production by allogeneic T cells.	Mercaptopurine	30-46	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-69	
25284689-3	2014	By using quantitative real-time PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA), we show that either ectopic expression of orphan nuclear receptor Nur77 or pharmacological activation of Nur77 by 6-mercaptopurine (6-MP) substantially inhibits ET-1 expression in human umbilical vein endothelial cells (HUVECs), under both basal and thrombin-stimulated conditions.	Mercaptopurine	207-223	nuclear receptor subfamily 4 group A member 1	Homo sapiens	198-203	
15956351-3	2005	Recently, we found that the purine antimetabolite 6-Mercaptopurine (6-MP), which is widely used as an anti-neoplastic and anti-inflammatory drug, modulated the NR4A1-3 subfamily.	Mercaptopurine	50-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-165	
15956351-3	2005	Recently, we found that the purine antimetabolite 6-Mercaptopurine (6-MP), which is widely used as an anti-neoplastic and anti-inflammatory drug, modulated the NR4A1-3 subfamily.	Mercaptopurine	68-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	160-165	
20438716-10	2010	Finally, the expression of Nur77 increased along with that of p300, but decreased with induction of HDAC1 after treatment with epithelial growth factor, nerve growth factor, or 6-mercaptopurine, suggesting that the self-control of the acetylation status contributes to the transient induction of Nur77 protein.	Mercaptopurine	177-193	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-32	
17146432-0	2007	6-Mercaptopurine, an activator of Nur77, enhances transcriptional activity of HIF-1alpha resulting in new vessel formation.	Mercaptopurine	0-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	34-39	
16723716-7	2006	Finally, stretch-mediated proliferation was inhibited by 6-mercaptopurine, an agonist of TR3.	Mercaptopurine	57-73	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-92